Previous close | 26.02 |
Open | 26.64 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 26.64 - 26.64 |
52-week range | 25.04 - 32.76 |
Volume | |
Avg. volume | 8,670 |
Market cap | 42.283B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 45.15 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.26 (4.85%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland, May 13, 2024--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
OSAKA, Japan, May 09, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.